Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: Evidence from a managed care database in the United States

Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: Evidence from a managed care database in the United States

BACKGROUND: Data on the clinical and economic burden of eosinophilic granulomatosis with polyangiitis (EGPA) are limited. OBJECTIVE: To assess the real-world clinical and economic outcomes of patients diagnosed with EGPA vs patients with asthma (present in > 90% of EGPA cases) receiving treatment...

Full description

Bibliographic Details
Main Authors: Bell, C.F (Author), Blauer-Peterson, C. (Author), Mao, J. (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
adult
aged
Aged
algorithm
Article
asthma
Charlson Comorbidity Index
cohort analysis
controlled study
corticosteroid
corticosteroid therapy
cost of illness
Cost of Illness
Databases, Factual
disease burden
drug use
economic evaluation
economics
eosinophilic granuloma
eosinophilic granulomatosis with polyangiitis
factual database
female
Female
follow up
Granulomatosis with Polyangiitis
health care cost
health care utilization
health insurance
hospitalization
human
Humans
ICD-10-CM
ICD-9-CM
insurance
Insurance Claim Review
major clinical study
male
Male
managed care
Managed Care Programs
middle aged
Middle Aged
outcome assessment
propensity score
relapse
Retrospective Studies
retrospective study
United States
Wegener granulomatosis
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items